BSE filing, NSE: UGROCAP. Summary written from the filing by ALFA Finder's alert engine.
Ugro Capital Ltd: key numbers
- Share price
- ₹74.10
- Market cap
- ₹1,151 Cr
- Revenue (annual)
- ₹1,766 Cr
- Net profit (annual)
- ₹113.4 Cr
- P/E (TTM)
- 8.2×Sector 19.7×
- Promoter holding
- 2.88%+0.00% QoQ
- FII holding
- 7.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ugro Capital Ltd
All →Ugro Capital Debt & Borrowing: ₹1.17 Cr
Ugro Capital paid Rs.1.17 Crore of monthly interest on its NCDs, due 27 October 2026. This is routine servicing of existing debt for NCD holders.
- Value
- ₹1.17 Cr
Ugro Capital Debt & Borrowing: ₹2.08 Cr
Ugro Capital paid monthly NCD interest totalling Rs.2.08 Crore across two series on 23 October 2026. This is debt servicing, with no new capital raised.
- Value
- ₹2.08 Cr
Ugro Capital Debt & Borrowing: ₹141.6 Cr
Ugro Capital Ltd redeemed three NCD series totaling Rs.141.56 Crore at maturity on October 22, 2026. The redemption spans three non-convertible debenture tranches maturing that day.
- Value
- ₹141.6 Cr
Ugro Capital Debt & Borrowing: ₹3.78 Cr
Ugro Capital paid ₹3.78 Crore in interest across seven NCD series on October 22, 2026. All payments were made ahead of the due date.
- Value
- ₹3.78 Cr
Ugro Capital Acquisition
UGRO Capital announced that the NCLT has scheduled the final hearing for the company's amalgamation scheme with Profectus Capital Private Limited on 20th November 2026.
Ugro Capital Debt & Borrowing: ₹3.09 Cr
Ugro Capital successfully paid a total of ₹3.09 Crore as interest on three series of its non-convertible debentures. This regular debt obligation reflects the company's financial commitment.
- Value
- ₹3.09 Cr
Other other announcement announcements
All →Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.